BIOT:SW:SW-L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF (CHF)

ETF | Others |

Last Closing

USD 9.096

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.06 (-0.46%)

USD 1,244,681.59B
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.06 (-0.46%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.07 (-0.33%)

USD 226,274.25B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.07 (-0.33%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.06 (-0.22%)

USD 226,274.21B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.06 (-0.22%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-10.00 (-0.12%)

USD 134,034.93B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-10.00 (-0.12%)

USD 134,034.93B

ETFs Containing BIOT:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.29% 27% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.29% 26% F 29% F
Trailing 12 Months  
Capital Gain -1.94% 6% D- 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.94% 5% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.81% N/A N/A 7% C-
Dividend Return -5.81% N/A N/A 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.11% N/A N/A 51% F
Risk Adjusted Return -71.60% N/A N/A 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike